This result might imply that class I HDACs and their substrate ERK1/2 signaling cascade might be the target to modulate pathological cardiac fibrosis and hypertrophy that may lead to the development of DCM. This evidence concerns the gene MAPK3 and familial dilated cardiomyopathy.